In two days the voting will end to pick the top 12 finalists for Stem Cell Person of the Year 2014 Award. You can vote here. From the finalists I will have the tough decision of picking the winner. Check out who’s in the top 12 now and who the top few vote getters are. Will someone surge ahead in the last two days? The nominees have a great mix of backgrounds from all parts of the stem cell world both in terms of their missions and geographic …Read More
Michael West
With one week left to vote to pick the top 12 finalists for the Stem Cell Person of the Year 2014 Award, we have more than 2,800 votes in so far. From the top 12 vote-getters, I will choose the winner. This is the third year of this award. I self-fund this award out of my own pocket with the winner receiving $2,000. Voting closes at midnight on October 22nd. You can vote once per day here and see the evolving results. We have …Read More
Nominations have closed and we have more than two dozen nominations for Stem Cell Person of the Year 2014. It’s an exciting, diverse group including some news faces as well as nominees from years past as well. Happy Stem Cell Day! You can now vote for your choice for the top finalists in the poll below. One vote per IP address is allowed per day. Voting will end on October 22 at midnight. The winner of the voting may not be the overall winner of the …Read More
Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based therapy developed in Israel.” Cell Cure in its PR on this IND also listed three other key bullet points: “IND filed for Phase I/IIa dose escalation trial in patients …Read More
Can Google’s new anti-aging company, Calico, have you Googling at age 140? Don’t sell your burial plot just yet. The idea of anti-aging has been around for a very long time and efforts to combat aging have spanned millennia largely without any success so Calico (apparently short for California Life Company, which sounds more like an insurance company to me) faces long odds. Note too that Calico cats are not known for any particular predisposition to long life. Hmmm. Note that you might find …Read More
Who might make a fantastic new CIRM President? The California stem cell community is abuzz with this question. This new President will not only lead CIRM today, but also in all likelihood will steer CIRM in its new incarnation after 2017, what I’ve called CIRM 2.0. At least that would be ideal. CIRM has posted a position/candidate specification document here including a summary of the position that includes this statement: The President of CIRM must be a nationally recognized leader with a vision, scientific credibility, and …Read More
BioTime (BTX), via its subsidiary Asterias, has formally purchased the Geron (GERN) embryonic stem cell (ESC) research program and assets. Incidentally, Asterias in nature refers to a genus of sea stars including starfish and you can see it in their logo. Perhaps this was chosen given the amazing regenerative capacity of starfish? You may recall that Geron decided not to continue its ESC program despite having an active, FDA approved early clinical trial underway. There was great concern that the program could die, but …Read More